A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study

J. W. Goodwin, J. Crowley, H. J. Eyre, B. Stafford, K. A. Jaeckle, J. J. Townsend

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M 2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of Neuro-Oncology
Volume15
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Meningioma
Tamoxifen
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology
  • Neuroscience(all)

Cite this

Goodwin, J. W., Crowley, J., Eyre, H. J., Stafford, B., Jaeckle, K. A., & Townsend, J. J. (1993). A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. Journal of Neuro-Oncology, 15(1), 75-77. https://doi.org/10.1007/BF01050266

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas : A Southwest Oncology Group study. / Goodwin, J. W.; Crowley, J.; Eyre, H. J.; Stafford, B.; Jaeckle, K. A.; Townsend, J. J.

In: Journal of Neuro-Oncology, Vol. 15, No. 1, 1993, p. 75-77.

Research output: Contribution to journalArticle

Goodwin, JW, Crowley, J, Eyre, HJ, Stafford, B, Jaeckle, KA & Townsend, JJ 1993, 'A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study', Journal of Neuro-Oncology, vol. 15, no. 1, pp. 75-77. https://doi.org/10.1007/BF01050266
Goodwin, J. W. ; Crowley, J. ; Eyre, H. J. ; Stafford, B. ; Jaeckle, K. A. ; Townsend, J. J. / A phase II evaluation of tamoxifen in unresectable or refractory meningiomas : A Southwest Oncology Group study. In: Journal of Neuro-Oncology. 1993 ; Vol. 15, No. 1. pp. 75-77.
@article{9a50dfe80cdc466aa8b7185c21f223f7,
title = "A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study",
abstract = "Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M 2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5{\%}) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32{\%}) remained stable for a median duration of 31 + months while ten (53{\%}) demonstrated progression. Twenty-two percent (22{\%}) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.",
author = "Goodwin, {J. W.} and J. Crowley and Eyre, {H. J.} and B. Stafford and Jaeckle, {K. A.} and Townsend, {J. J.}",
year = "1993",
doi = "10.1007/BF01050266",
language = "English (US)",
volume = "15",
pages = "75--77",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A phase II evaluation of tamoxifen in unresectable or refractory meningiomas

T2 - A Southwest Oncology Group study

AU - Goodwin, J. W.

AU - Crowley, J.

AU - Eyre, H. J.

AU - Stafford, B.

AU - Jaeckle, K. A.

AU - Townsend, J. J.

PY - 1993

Y1 - 1993

N2 - Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M 2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

AB - Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M 2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

UR - http://www.scopus.com/inward/record.url?scp=0027414013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027414013&partnerID=8YFLogxK

U2 - 10.1007/BF01050266

DO - 10.1007/BF01050266

M3 - Article

C2 - 8455065

AN - SCOPUS:0027414013

VL - 15

SP - 75

EP - 77

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -